TickerFacts.

Company research / JAZZ

Jazz Pharmaceuticals plc (JAZZ)

Build a valuation ↗↓ Download CSV

CIK 0001232524 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Jazz Pharmaceuticals plc reported revenue of $4.27B. Revenue grew 4.9% from the prior annual period.

Key ratios (year ended 2025-12-31)

-10.1%
Operating margin
-8.3%
Net margin
-8.2%
Return on year-end equity
4.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-09

Headquarters locality: Ireland · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B$2.36B$2.16B$1.89B$1.62B$1.49B
R&D Expense$782.74M$884.00M$849.66M$590.45M$505.75M$335.38M$299.73M$226.62M$198.44M$162.30M
Operating Income-$430.24M$716.63M$578.58M-$65.53M$170.28M$378.07M$532.37M$614.84M$528.84M$591.65M
Depreciation & Amortization$41.60M$32.80M$30.40M$30.30M$26.70M$18.70M$15.30M$15.20M$13.10M$11.80M
EBITDA-$388.64M$749.43M$608.98M-$35.23M$196.98M$396.77M$547.67M$630.04M$541.94M$603.45M
Net Income-$356.15M$560.12M$414.83M-$224.06M-$329.67M$238.62M$523.37M$447.10M$487.85M$396.83M
EPS (Diluted)-$5.84$8.65$6.10-$3.58-$5.52$4.22$9.09$7.30$7.96$6.41
Total Assets$11.66B$12.01B$11.39B$10.84B$12.30B$6.54B$5.54B$5.20B$5.12B$4.80B
Long-Term Debt$5.36B$6.11B$5.71B$5.72B$6.05B$2.09B$1.61B$1.60B$1.58B$2.03B
Shareholders' Equity$4.32B$4.09B$3.74B$3.09B$3.97B$3.66B$3.11B$2.76B$2.71B$1.88B
Cash & Equivalents$1.39B$2.41B$1.51B$881.48M$591.45M$1.06B$637.34M$309.62M$386.04M$365.96M
Operating Cash Flow$1.36B$1.40B$1.09B$1.27B$778.51M$899.65M$776.40M$798.90M$693.09M$592.39M
Capital Expenditures$58.75M$38.07M$23.96M$29.05M$27.64M$15.00M$40.13M$20.37M$28.95M$9.69M
Free Cash Flow$1.30B$1.36B$1.07B$1.24B$750.87M$884.64M$736.27M$778.53M$664.14M$582.70M
Share Repurchases$125.02M$311.43M$269.76M$54.0K$0$146.54M$301.45M$523.67M$98.80M$278.30M
Shares Outstanding61.44M60.63M62.26M63.21M61.63M56.17M56.14M57.70M58.90M59.82M
Weighted Average Diluted Shares60.98M66.01M72.07M62.54M59.69M56.52M57.55M61.22M61.32M61.87M
EPS (Basic)-$5.84$9.06$6.55-$3.58-$5.52$4.28$9.22$7.45$8.13$6.56

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView